FDA Looks Ahead and Back on Orally Inhaled and Nasal Generic Drugs
By Zachary Brennan -
Published 15 January 2018
The US Food and Drug Administration (FDA) has come a long way when it comes to locally acting orally inhaled and nasal drug products (OINDPs) and in the next five years of generic drug user fees, the agency is looking at further progress on some unique challenges, according to a regulatory science report on OINDPs.
Categories: News, US, FDA, Generic drugs, Regulatory intelligence, Regulatory strategy, Research and development
Tags: OINDP, locally acting orally inhaled and nasal drug products